Last reviewed · How we verify

NCT05116878: EFFORTS

Enhancing Facial Nerve Function With Omega-3 After Resection of Vestibular Schwannoma

Terminated NA Last updated 8 September 2023
What this trial tests

NA trial testing Omega-3 in Vestibular Schwannoma in 15 participants. Terminated before completion.

Timeline
1 November 2021
Primary endpoint
2 August 2023
2 August 2023

Quick facts

Lead sponsorMayo Clinic
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment15
Start date1 November 2021
Primary completion2 August 2023
Estimated completion2 August 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Vestibular Schwannoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this research is to develop a therapeutic agent to help improve facial nerve outcomes and ultimately improve long-term quality-of-life following surgical resection of vestibular schwannomas. It is possible the therapeutic agent may impact tumor control rates as well, and this will also be studied. Using rigorous scientific methods, we will assess whether these factors are impacted by the treatment agent (Omega-3) versus placebo control (cellulose).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Omega-3

Trials testing the same drug.

Other recruiting trials for Vestibular Schwannoma

Currently open trials in the same condition.

Other Mayo Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05116878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing